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Background
Juvenile dermatomyositis (JDM) is a rare, chronic
inflammatory disease. Anti-TNF-a agents are increas-
ingly being used to treat disease that is refractory to
other treatments. There is a lack of literature regarding
the effectiveness of anti-TNF-a agents in JDM.
Aim
To assess the response of refractory JDM patients to
anti-TNF-a agents.
Methods
The Juvenile Dermatomyositis National (UK and Ire-
land) Cohort Biomarker Study and Repository for Idio-
pathic Inflammatory Myopathies database was searched
for patients treated with anti-TNF-a agents.
Results
INFLIXIMAB: 28/30(93%) patients had data available.
Indicators for starting infliximab were: muscle weakness
(70%), non-ulcerative skin disease (57%), calcinosis
(33%), and nail fold changes (30%). All patients with a
low CMAS (n=18) improved. Physician VAS improved
in 20/26(77%), CHAQ score in 11/16(69%), skin disease
in 19/23(83%), calcinosis in 6/13(46%) and muscle
enzymes in 6/10(60%). Prednisolone dose decreased in
17/21(81%).
ADALIMUMAB: 10/11(91%) had previously been
treated with infliximab. 6/10(60%) were changed to
improve disease control: 4 had persistent skin disease, 2
improved; 3 had progressive calcinosis, 1 improved, 2
remained stable. 8/9(89%) maintained previous gains or
made further improvement in other parameters other
than skin and calcinosis.
ETANERCEPT: 4/7(57%) patients had data available. 2
improved, 2 were switched to infliximab, one for
increasing calcinosis, one for compliance issues.
Conclusions
Infliximab provides clinical benefit to patients with JDM
refractory to other treatments; particularly muscle weak-
ness. Switching to adalimumab benefited some patients;
gains made on infliximab were maintained in most
cases.
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